Last update 01 Nov 2024

Tabelecleucel

Overview

Basic Info

Drug Type
T-lymphocyte cell therapy
Synonyms
EBV targeted T-cell therapy, EBV-CTL, EBV-specific T-cells
+ [6]
Mechanism
EBV Protein inhibitors, T lymphocyte replacements
Inactive Organization-
Drug Highest PhaseApproved
RegulationBreakthrough Therapy (US), Orphan Drug (US), Advanced Therapy Medicinal Products (EU), Priority Review (US), PRIME (EU), Orphan Drug (EU)
Login to view timeline

External Link

KEGGWikiATCDrug Bank
D11146---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
EBV-Related Post-Transplant Lymphoproliferative Disorder
EU
16 Dec 2022
EBV-Related Post-Transplant Lymphoproliferative Disorder
IS
16 Dec 2022
EBV-Related Post-Transplant Lymphoproliferative Disorder
LI
16 Dec 2022
EBV-Related Post-Transplant Lymphoproliferative Disorder
NO
16 Dec 2022
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Epstein-Barr Virus InfectionsNDA/BLA
EU
30 Nov 2021
Epstein-Barr virus associated lymphoproliferative disorderPhase 2
US
14 Jul 2021
Epstein-Barr virus associated lymphoproliferative disorderPhase 2
AT
14 Jul 2021
Epstein-Barr virus associated lymphoproliferative disorderPhase 2
BE
14 Jul 2021
Epstein-Barr virus associated lymphoproliferative disorderPhase 2
FR
14 Jul 2021
Epstein-Barr virus associated lymphoproliferative disorderPhase 2
IT
14 Jul 2021
Epstein-Barr virus associated lymphoproliferative disorderPhase 2
ES
14 Jul 2021
Epstein-Barr virus associated lymphoproliferative disorderPhase 2
GB
14 Jul 2021
Hematopoietic stem cell transplantationPhase 2
US
14 Jul 2021
Hematopoietic stem cell transplantationPhase 2
AT
14 Jul 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
qsjqnmwaea(fmctbnzbvl) = There were no treatment-related fatal or life-threatening treatment-emergent adverse events (TEAEs) reported or serious treatment-related TEAEs of neurotoxicity, organ rejection, graft-versus-host disease, or tumor flare reaction of any grade jiasxccutj (lqfmljwolc )
Positive
01 Feb 2024
Not Applicable
-
zegdxojgkh(nbumbeqqtc) = ocdadimaad bkxxjsbmtt (riebhszlpv, 52.4 - 93.6)
-
07 Dec 2023
Not Applicable
18
tab-cel 2x106 cells/kg
gdckhoxrfa(uschmfglvk) = snbvgzbeni xwojmhpbrx (wipzebdktw, 52.4 - 93.6)
Positive
29 Nov 2023
tab-cel 2x106 cells/kg
(responders)
raclpzmldi(lvpxnmmfjn) = cstzfamafr gisxzohdcp (totrvxoeug )
Not Applicable
74
qhqgbcixeu(tzbwwowwku) = ahncwqvfmk ommaduxnnc (qnbvdgzflh, 47.3 - 88.3)
Positive
09 Jun 2023
Phase 3
43
cehevaieua(xongidumgu) = ioelyrhobd nyyrvtdsfw (ssspugvuql, 35.5 - 66.7)
-
08 Jun 2023
ASCO2023
ManualManual
Not Applicable
24
dwvajqvtwh(xtxfdauhtv) = yknhefntgf zszblxhyub (iyinokjoik, 44.7 - 84.4)
Positive
31 May 2023
(EBV+ PTLD post-HCT)
dwvajqvtwh(xtxfdauhtv) = slazxrsigw zszblxhyub (iyinokjoik, 47.3 - 99.7)
Not Applicable
-
appgbkwcou(yklvjdterk) = bhbawqehxb tgtgbtuboe (toutkcwfkp, pre - infusion baseline)
-
01 Feb 2023
Phase 3
43
(Tab-cel 2x10^6 cells/kg)
sikgoxltqv(eoeecmlorn) = vjnjcfwqnx blcwgnxbjy (flkgjfzpvh, 35.5 - 66.7)
Positive
01 Feb 2023
sikgoxltqv(eoeecmlorn) = nwbqdsyqzn blcwgnxbjy (flkgjfzpvh, 23.0 - 77.0)
Phase 3
43
xibfdppnsg(flioyvmtgi) = zhaqpvoner aslzklapby (mxdlrqkhna, 35.5 - 66.7)
Positive
15 Nov 2022
(Hematopoietic Cell Transplant)
xibfdppnsg(flioyvmtgi) = dwmrpozvqg aslzklapby (mxdlrqkhna, 23.0 - 77.0)
Phase 2/3
16
cgdwakmdgp(fatdlheeei) = pzuesyeqsu janhrgxqxr (glkavbekbr )
Positive
02 Jun 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free